VivoSim Labs (VIVS) Net Equity Issued and Repurchased (2010 - 2026)
VivoSim Labs (VIVS) posted quarterly Net Equity Issued and Repurchased of $3.0 million for Q1 2026, down 5.9% year-over-year from $3.2 million in Q1 2025, and up 66.5% quarter-over-quarter from $1.8 million in Q4 2025.
VivoSim Labs (VIVS) Net Equity Issued and Repurchased (2010 - 2026) Analysis & Trends
VivoSim Labs' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Net Equity Issued and Repurchased fell 5.9% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $8.4 million (down 8.24% YoY), while the FY2026 annual figure was $4.8 million, down 45.65% from the prior year.
- Net Equity Issued and Repurchased for Q1 2026 stood at $3.0 million, up from $1.8 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $6.2 million in Q2 2024, with the low at -$371000.0 in Q3 2024.
- The 4-year median for Net Equity Issued and Repurchased is $1.8 million (2025), against an average of $1.9 million.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased sank 91.47% in 2024, then surged 1700.0% in 2025.
- VivoSim Labs' Net Equity Issued and Repurchased stood at $1.2 million in 2023, then tumbled by 91.47% to $100000.0 in 2024, then soared by 1700.0% to $1.8 million in 2025, then surged by 66.5% to $3.0 million in 2026.
- Business Quant data shows VIVS's Net Equity Issued and Repurchased at $3.0 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.19 Mn |
| Dec 31, 2024 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | -371,000.00 |
| Sep 30, 2024 | -371,000.00 |
| Jun 30, 2024 | 6.25 Mn |
| Jun 30, 2024 | 6.25 Mn |
| Mar 31, 2024 | 264,000.00 |
| Mar 31, 2024 | 264,000.00 |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |